Evidence map›Paper›PMID 23892326›Full record

ArticleBone marrow transplantation2014

Prophylaxis and treatment of GVHD: EBMT-ELN working group recommendations for a standardized practice.

T Ruutu, A Gratwohl, T de Witte, B Afanasyev, J Apperley, A Bacigalupo, F Dazzi, P Dreger, R Duarte, J Finke and 15 more

Erratum issued 2 registry-linked trialsAbstract read
PubMed Publisher
In one paragraph

Article in Bone marrow transplantation, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to 2 registered trials, which are not on this map. Cited by 148 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
148citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07576699 phase1 / phase2not yet recruitingnot on this mapstarted 2026, after this paper: background citation

CK0802 for Treatment of Steroid Refractory Graft vs. Host Disease (GVHD)

TypeinterventionalSponsorCellenkos, Inc.Ran2026 to 2029Enrolled12ConditionsSteroid Refractory Graft Versus Host DiseaseArmsCK0802 (Allogeneic, Cryopreserved, Cord blood-derived T-regulatory cells, cells that are not HLA matched)
NCT07708987 phase2recruitingnot on this mapstarted 2023, after this paper: background citation

A Phase II Clinical Trial of Standardized Withaferin-A for the Treatment of Steroid Refractory Acute Graft Versus Host Disease

TypeinterventionalSponsorTata Memorial CentreRan2023 to 2028Enrolled34ConditionsHematological Malignancy, GVHD - Graft-Versus-Host Disease, Steriod RefractoryArmsStandardized Withaferin A (SWA)
3 · Its place in the literature

Who cites it

148 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. The Role of Biomarkers in the Diagnosis and Risk Stratification of Acute Graft-versus-Host Disease: A Systematic Review.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2016
    Pooled it
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Long-term outcomes of patients with persistent indolent B cell malignancies undergoing nonmyeloablative allogeneic transplantation.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2015
    Trial
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

88 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

  • Erratum issued
    Dosage error in article text
5 · Who and what money

Authors and funding

25 authors.

T RuutuDepartment of Medicine, Helsinki University Central Hospital, Helsinki, Finland.
A GratwohlHematology, Medical Faculty, University of Basel, Basel, Switzerland.
T de WitteDepartment of Tumor Immunology, Nijmegen Centre for Molecular Life Sciences, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands.
B AfanasyevR. Gorbacheva Memorial Institute of Oncology, Hematology and Transplantation, St Petersburg State Medical I.P.Pavlov University, St Petersburg, Russia.
J ApperleyDepartment of Haematology, Hammersmith Hospital, Imperial College London, London, UK.
A BacigalupoDivision of Hematology, IRCCS San Martino, Genova, Italy.
F DazziDepartment of Medicine, Imperial College London, Hammersmith Campus, London, UK.
P DregerDepartment of Medicine V, University of Heidelberg, Heidelberg, Germany.
R DuarteInstitut Català d'Oncologia, L'Hospitalet de Llobregat, Barcelona, Spain.
J FinkeDepartment of Hematology, Oncology and Stem Cell Transplantation, University Medical Center, Freiburg, Germany.
L GarderetService d'Hematologie, Hôpital Saint Antoine, Paris, France.
H GreinixDepartment of Internal Medicine I, Medical University, Vienna, Austria.
E HollerDepartment of Haematology/Oncology, University Hospital Regensburg, Regensburg, Germany.
N KrögerDepartment of Stem Cell Transplantation, University Cancer Centre Hamburg, Hamburg, Germany.
A LawitschkaSt Anna Children's Hospital, Vienna, Austria.
M MohtyService d'Hématologie Clinique et de Thérapie Cellulaire, Hopital Saint Antoine, Universite Pierre et Marie Curie, INSERM, Paris, France.
A NaglerHematology Division, Tel-Aviv University, Sheba Medical Center, Tel-Hashomer, Israel.
J PasswegCenter for Stem Cell Transplantation, University Hospital Basel, Basel, Switzerland.
O RingdénCenter for Allogeneic Stem Cell Transplantation, Karolinska Institute, Karolinska University Hospital, Huddinge, Sweden.
G SociéDepartment of Hematology-Transplantation, Saint-Louis Hospital, Paris, France.
J SierraHaematology Service, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.
A SuredaHaematology Department, Addenbrookes Hospital, Cambridge, UK.
W Wiktor-JedrzejczakDepartment of Hematology, Oncology and Internal Diseases, Medical University of Warsaw, Warsaw, Poland.
A MadrigalAnthony Nolan Research Institute, Royal Free Hospital, London, UK.
D NiederwieserDepartment of Hematology/Oncology and Hemostasiology, University of Leipzig, Leipzig, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

GVHD remains the major impediment to broader application of allogeneic haematopoietic SCT. It can be prevented completely, but at the expense of other complications, rejection, relapse or delayed immune reconstitution. No optimal prevention or treatment method has been defined. This is reflected by enormous heterogeneity in approaches in Europe. Retrospective comparisons between different policies, although warranted, do not give definite answers. In order to improve the present situation, an European Group for Blood and Marrow Transplantation and the European LeukemiaNet working group has developed in a Delphi-like approach recommendations for prophylaxis and treatment of GVHD in the most common allogeneic transplant setting, transplantation from an HLA-identical sibling or unrelated donor for standard risk malignant disease. The working group proposes these guidelines to be adopted as routine standard in transplantation centres and to be used as comparator in systematic studies evaluating the advantages and disadvantages of practices differing from these recommendations.

Indexed as

Graft vs Host DiseaseHematopoietic Stem Cell TransplantationHumansTransplantation, AutologousTransplantation Conditioning

Identifiers

PMID23892326

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.